A.L. Catapano Research Group

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.

Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, Stroes ES, MacDougall D, Zhao X, Catapano AL

Eur J Prev Cardiol. 2019 Jul 29:2047487319864671.

Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia.

Perez de Isla L, Ray KK, Watts GF, Santos RD, Alonso R, Muniz-Grijalvo O, Diaz-Diaz JL, Badimon L, Catapano AL, Mata P

Atherosclerosis. 2019 May 4;286:40-45.

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.

Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL, Ballantyne CM

N Engl J Med. 2019 Mar 14;380(11):1022-1032.

Pentraxin 3 deficiency protects from the metabolic inflammation associated to diet-induced obesity.

Bonacina F, Moregola A, Porte R, Baragetti A, Bonavita E, Salatin A, Grigore L, Pellegatta F, Molgora M, Sironi M, Barbati E, Mantovani A, Bottazzi B, Catapano AL, Garlanda C, Norata GD

Cardiovasc Res. 2019 Mar 12. pii: 5374872.

High-density lipoprotein cholesterol levels, cardiovascular disease risk, and cancer: a relation which does not apply to all?

Catapano AL, Pirillo A, Norata GD

Cardiovasc Res. 2019 Jan 1;115(1):6-7.

A.L. Catapano Research Group

Department of Pharmacological and Biomolecular Sciences, University of Milan